Feels weird replying to myself, but just so others got the crux of this, the retrospective study looked at a claims database (So Health Insurance), Lab database & 49% of patients did not have an official dx of CKD even though lab results may have shown otherwise.
This is huge evidence for Doctors & US health funds to get on top of CKD/DKD early, not just for patient benefit, but also for huge costs in ESKD in dialysis & kidney transplant. PIQ had also informed us some time ago there was interest from US Health Insurance funds in PromarkerD & results of this retrospective study, with Janssen whom we are already collaborating with. Is this just sheer coincidence, or are we seeing a building body of evidence for predictive testing?
PIQ Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)